Alzheimer’s Disease Neuroimaging Initiative

5586 Total Publications

Year	Title	Author	Journal
2010	The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board	Schmidt ME1, Siemers E, Snyder PJ, Potter WZ, Cole P, Soares H.	Journal Alzheimers Dement;
2010	Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials	Schneider, L. S., Kennedy, R. E., & Cutter, G. R.	Journal Alzheimer's and Dementia;
2010	Discovery and use of efficient biomarkers for objective disease state assessment in Alzheimer’s disease	van Gils M1, Koikkalainen J, Mattila J, Herukka S, Lotjonen J, Soininen H.	Journal Int J Geriatr Psychiatry;
2010	The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes	Beckett, L. a., Harvey, D. J., Gamst, A., Donohue, M., Kornak, J., Zhang, H., & Kuo, J. H.	Journal Alzheimer's and Dementia;
2010	Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials	Schneider, L. S., Kennedy, R. E., & Cutter, G. R.	Journal Alzheimer's and Dementia;
2010	Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study.	Tosun, D., Schuff, N., Truran-Sacrey, D., Shaw, L. M., Trojanowski, J. Q., Aisen, P., … Weiner, M. W.	Journal Neurobiology of Aging;
2010	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging	Rowe CC1, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL	Journal Neurobiol Aging;
2010	Boosting power for clinical trials using classifiers based on multiple biomarkers	Kohannim, O., Hua, X., Hibar, D. P., Lee, S., Chou, Y. Y., Toga, A. W., … Thompson, P. M.	Journal Neurobiology of Aging;
2010	SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer’s Disease	Cruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Cruchaga, C., Kauwe, J. S. K., … Goate, A. M.	Journal PLoS Genetics;
2010	Integrating ADNI results into Alzheimer's disease drug development programs.	Cummings, J. L.	Journal Neurobiology of Aging;